{
    "nctId": "NCT00566085",
    "briefTitle": "New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer",
    "officialTitle": "Molecular Breast Imaging: Evaluation of a New Technique Using Scintimammography as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer - A Pilot Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "To document that pre- and post-neoadjuvant therapy tumor size can be satisfactorily assessed by molecular breast imaging and corresponds to tumor size evaluation by conventional breast imaging procedures (mammogram, ultrasound, MRI).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women age 18 - 90\n* Women with breast cancer scheduled to undergo neoadjuvant chemotherapy therapy or neoadjuvant hormone therapy\n* Women who have undergone any breast imaging procedure, and in whom a repeat imaging procedure is planned prior to definite surgery\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Unable to understand or sign a consent form\n* Physically unable to sit upright and still for 40 minutes",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}